Serum PDGF-AB in pleural mesothelioma

Rosa Filiberti, Paola Marroni, Monica Neri, Andrea Ardizzoni, Pier Giacomo Betta, Mara A. Cafferata, Pier Aldo Canessa, Riccardo Puntoni, Giovanni Paolo Ivaldi, Michela Paganuzzi

Research output: Contribution to journalArticlepeer-review


Overexpression of platelet-derived growth factor (PDGF) has been observed in lung and pleural tumors. The aim of this study was to evaluate the diagnostic and prognostic role of serum PDGF in pleural mesothelioma (PM). Four groups of subjects were studied: 93 malignant PM patients, 33 primary non small cell lung cancer patients, 51 subjects exposed to asbestos, defined as high-risk controls, and 24 healthy controls. PDGF-AB mean concentration was higher in PM patients (45.8 ng/ml) than in high-risk controls (33.1 ng/ml) and healthy controls (26.8 ng/ml). Using the cut-off level of 49.8 ng/ml, corresponding to the mean + 2SD of PDGF-AB in healthy controls, 43% of PM patients showed positive PDGF-AB levels. Survival was evaluated in 82 PM patients. At the end of the follow-up (median 9.8 months) 80.5% of patients had died. Median survival was 13.1 and 7.9 months for patients with PDGF-AB lower and higher than the cut-off, respectively. Adjusting for age, sex, histology and platelet count, positive PDGF-AB levels were associated with lower survival (OR = 1.2, 95%CI: 0.9-1.6), even if not significantly so. In conclusion, serum PDGF may represent a useful additional parameter to prognostic factors already available for PM.

Original languageEnglish
Pages (from-to)221-226
Number of pages6
JournalTumor Biology
Issue number5
Publication statusPublished - Sep 2005


  • Asbestos
  • Biomarker
  • Growth factor
  • PDGF
  • Pleural mesothelioma
  • Prognosis
  • Serum

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Serum PDGF-AB in pleural mesothelioma'. Together they form a unique fingerprint.

Cite this